Scarinci Hollenbeck Article Library

Results for fda articles

Key Takeaways from the FDA’s Review of CBD Products for Mislabeling and Adulteration

Key Takeaways from the FDA’s Review of CBD Products for Mislabeling and Adulteration

Author: Daniel T. McKillopDate: July 27, 2020

The U.S. Food and Drug Administration (FDA) recently sent an overdue report to Congress regarding its review of cannabidiol (CBD) products for mislabeling and adulteration. The FDA report revealed that mislabeling and adulteration are not widespread, it did find that the actual CBD content in many products did not match the content described in these products’ labeling.

According to the FDA, its findings support the need for additional studies. “FDA believes that understanding the characteristics of marketed CBD products is critical to making informed decisions about how best to protect public health in the current marketplace,” the report states.

scarinci hollenbeck diamond logo

Get the latest from our attorneys!

As the legal world continues to evolve, it is important to stay aware of its various and regular updates.
Sign up to our mailing list